marker of functional iron deficiency in HD patients concentration and ( 2) cellular volume. Cells with cellular during rHuEpo therapy was first described by haemoglobin concentrations <28 g/dl were considered to be Macdougall et al. [1 ] . Macdougall [2 ] stated that if hypochromic; microcytic cells were those with a cell volume the proportion of hypochromic erythrocytes rises <60 fl.
above 10% during erythropoietin therapy, more intens-ZPP was measured in a front face haematofluorometer ive iron supplementation may be required. Schaefer (AVIV Biomedical Company, Lakewood, NJ ) with washed and Schaefer [3 ] found decreased hypochromic RBC erythrocytes to remove fluorescing uraemic interference from (<1%) in iron overloaded patients and increased EDTA-treated blood, which would result in overestimating ZPP using fluorescence measurements by haematofluoromehypochromic RBC (>22%) in patients with severe iron try [6 ] . The normal range in non-anaemic healthy volunteers deficiency. rHuEpo treatment without iron was 22.7±9.8 mmol/mol haem [ 7] . Serum ferritin was meassupplementation induced an increase in hypochromic ured by enzyme-linked immunoadsorbent assays (normal RBC from normal levels to 15.3%. This increase was range in non-renal patients 30-300 mg/l for men and readily reversed (5.5% after 4 weeks) when intravenous 25-150 mg/l for women). CRP was measured using a nepheloiron (750 mg iron within 4 weeks) was added to the metric method (normal value <8 mg/l). therapeutic regimen. The authors concluded that measurement of the percentage of hypochromic RBC is a Statistics reliable tool to detect iron deficiency [3 ] . By contrast, Sunder-Plassmann et al. iron. We compared the results with plasma zinc protoporphyrin levels, a rather inert parameter due to the
Results
considerable half-life of red blood cells.
EÂect of ferrogluconate on red blood cells

Subjects and methods
The percentage of hypochromic RBC was not normally A total of 70 HD patients (44 male, 26 female) without distributed in the 70 HD patients; instead, there was a blood loss either from gastrointestinal bleeding (negative clear right-sided tail. The median percentage of faecal occult blood by three consecutive tests) or from the hypochromic RBC at baseline was 6.1% with a range vascular access, and without surgery, infectious diseases of 0.2-33.7%. Initially we found that the percentage (negative C-reactive protein tests in 55 patients, positive of the hypochromic RBC was ∏5.0% in 28 patients C-reactive protein tests in 15 patients without fever and (median 2.9%), between 5.0 and 10.0% (>5.0∏10.0%) clinical signs or symptoms) or malignancies (negative tumour in 25 patients (median 6.8%), and >10.0% in 17 marker screening) completed the study. These patients were patients (median 13.6%). After 4 weeks of i.v. iron 20-88 years of age (57.1±15.3 years, mean±SD) and had supplementation with 80 mg ferrogluconate/week the been on HD for 66.3±47.9 months. None of the participants median percentage of hypochromic RBC decreased to had conditions, known to cause anaemia except for renal failure, e.g. serum aluminium levels >50 mg/l, desferriox-2.4% with a range of 0.2-13.7%. There was no further amine therapy, or deficient serum concentrations of vitamin decline during the following 8 weeks despite ongoing B 12 or folic acid.
i.v. iron supplementation ( Table 1) . At the end of the During the study period of 12 weeks, each patient received study the percentage of hypochromic RBC was ∏5.0% an i.v. iron dose of 80 mg/week (2×40 mg iron III sodium in 80% of the patients (median 1.9%, n=56 ) and gluconate complex, 3.2 ml ampoule FerrlecitA, Nattermann, between 5.0 and 10.0% in 16% of the patients (median Kö ln, Germany) during the first 8 weeks, and then 8.1%, n=11 ). In only 4% of the patients was the of hypochromic RBC. The rHuEpo dose in these was also comparable between both groups of patients; however, at the end of the study median serum ferritin patients with absolute iron deficiency was 1444±2006 IU/week at baseline and 888± level was significantly higher in the patients treated with rHuEpo than in non-rHuEpo treated patients 1166 IU/week at the end of the study following 800 mg of i.v. iron supplementation. The haemoglobin concen-(median 560 mg/l, range 96-1020 mg/l vs median 288 mg/l, range 154-792 mg/l, P<0.01). The ZPP levels tration was nearly constant during the study in these patients (10.9±1.9 g/dl vs 11.7±1.7 g/dl, P=n.s.); the were comparable at baseline and at the end of the study and there was no significant diÂerence between median serum ferritin level increased from 56 mg/l (range 20-98 mg/l ) to 201 mg/l (range 96-345 mg/l ) but rHuEpo-treated patients and patients not receiving rHuEpo (Table 2 ) . the median ZPP level remained unchanged ( 47.0 mmol/mol haem, range 2-128 mmol/mol haem at baseline vs 45.0 mmol/mol haem, range 14-117 EÂect of ferrogluconate on CRP-positive and CRPmmol/mol haem at the end of the study).
negative patients There was no correlation between ZPP levels and At baseline 15 patients (21.4%) had positive CRP tests, the percentage of hypochromic RBC at any time during but no clinical signs and symptoms to explain them. the study (data not shown). During the study the These patients had the same percentage of hypochmedian ZPP level declined rather uniform; in patients romic RBC at the start and after 4 weeks as patients with hypochromic RBC∏5.0% from 47.0 mmol/mol with negative CRP tests, but had significantly higher haem (range 4-282 mmol/mol haem) to 35.5 mmol/mol percentages of hypochromic RBC after 8 weeks haem (range 10-257 mmol/mol haem), in patients with (median 3.0%, range 0.4-14.3% vs median 7.0%, range hypochromic RBC levels between 5.0 and 10.0% from 1.5-15.9%, P<0.05) and 12 weeks (median 2.0%, 49.0 mmol/mol haem (range 1-122 mmol/mol haem) to range 0.2-9.0% vs median 4.7%, range 1.2-12.3%, 40.5 mmol/mol haem (range 13-117 mmol/mol haem) P<0.01) of i.v. iron supplementation ( Figure 2 ). The and in patients with hypochromic RBC>10% from ZPP levels and the serum ferritin levels at baseline and 59 mmol/mol haem (range 3-386 mmol/mol haem) to at the end of the study were comparable between the 51.0 mmol/mol haem (range 13-255 mmol/mol haem).
CRP-positive and the CRP-negative patients (data not shown). EÂect of ferrogluconate, with and without rHuEpo, on iron parameters EÂect of ferrogluconate on rHuEpo dosage: significance In the 52 patients who were placed on i.v. rHuEpo of hypochromic RBC therapy three times weekly at the beginning of the study the rHuEpo dose decreased from Patients with hypochromic RBC>10.0% at baseline received significantly lower rHuEpo doses after 4, 8 3924±2217 IU/week (mean 60 IU/kg body weight per week) to 3442±2226 IU/week (mean 53 IU/kg and 12 weeks of i.v. iron supplementation than did those patients with hypochromic RBC∏5.0%. There body weight per week) after 12 weeks of iron supplementation. The patients on rHuEpo therapy had was no significant diÂerence in the rHuEpo doses at baseline. The mean rHuEpo dose could be reduced by initially a comparable median percentage of the hypochromic RBC as those patients without rHuEpo 8.5% in patients with hypochromic RBC∏5% (from 3241±2214 IU/week to 2965±2195 IU/week), by ( 5.4 vs 6.8%, P=n.s.). The decline in hypochromic RBC during the first 4 weeks and the median values 11.3% in patients with hypochromic RBC between 5.0 and 10.0% (from 2680±2410 IU/week to 2375± after 8 weeks were also comparable in both groups. All patients with a higher initial percentage of hypoch-2242 IU/week) and by 23.4% in patients with hypochromic RBC>10.0% (from 2764±3363 IU/week to romic RBC had also a higher percentage at the end of the study. Patients on rHuEpo had a significantly 2117±3079 IU/week) ( Figure 3 ) .
A stepwise analysis of data from patients with lower percentage of hypochromic RBC at 4 and 12 weeks than patients without rHuEpo therapy hypochromic RBC between 5.0 and 10.0% was performed. We found that, at 4, 8 and 12 weeks after the ( Table 2 ) . At baseline the median serum ferritin level i.v. iron supplementation, the rHuEpo doses needed to maintain target haemoglobin values were significantly lower (P<0.05) in patients with hypochromic RBC>6.0% than in patients with hypochromic RBC<6.0% ( Table 3 ). The haemoglobin concentrations between the two groups were not significantly diÂerent.
EÂect of ferrogluconate on rHuEpo dosage: significance of serum ferritin Median serum ferritin level increased from 213 mg/l (range 20-858 mg/l ) to 489 mg/l (range 96-1020 mg/l ) after 12 weeks of i.v. iron supplementation. The cutoÂ for serum ferritin at the end of the study was selected by repeated tests that divided the patients into one with high and one with low rHuEpo doses. The minimum of the P values was found at a discriminating point of 290 mg/l serum ferritin. In those patients with serum ferritin levels from 96-290 mg/l at the end of the study (median 251.5 mg/l, n=18), that is, the first quartile of the serum ferritin levels after i.v. iron supplementation, rHuEpo doses were significantly lower than in patients with serum ferritin levels between 290 and 1020 mg/l (median 601.0 mg/l, n=52 ). Haemoglobin levels were not significantly diÂerent in the two groups at baseline. There was a significantly higher haemoglobin level at 8 weeks, however, and a significantly higher haematocrit at 12 weeks in those patients with low serum ferritin after i.v. iron supplementation, despite the significantly reduced rHuEpo doses in this particular group (Table 4 ) . At baseline, rHuEpo doses were 48% lower in patients with serum ferritin levels <290 mg/l than in those with levels >290 mg/l at the end of the study. After 4 weeks, this diÂerence increased to 54% and remained so until the end of the study. Throughout the study, there were significantly fewer rHuEpo-treated patients with serum ferritin <290 mg/l than with serum ferritin levels>290 mg/l ( baseline P=0.002; 12 weeks P= 0.009). At the end of the study the rHuEpo dose significantly declined in both groups: from 1722± 2321 IU/week to 1333±1878 IU/week (P<0.05) in patients with serum ferritin levels <290 mg/l and from 3333±2574 IU/week to 2960±2514 IU/week (P<0.01) in patients with serum ferritin levels >290 mg/l. There was a comparable degree of response (defined as 10% increase of haemoglobin or 20% decrease of rHuEpo dose) in both groups. The ZPP levels were comparable at baseline and decreased only moderately during the study but there was no significant diÂerence between the two groups of patients.
Only 35% (n=18) of the patients who were on rHuEpo (n=52) displayed a decrease in the rHuEpo dose during the study. In these patients there was a significant negative correlation between the increase of serum ferritin and the decrease of rHuEpo (Figure 4 ) . The mean reduction of the rHuEpo dose was 37%, from 4000 to 2500 IU/week. 1rHuEpo doses (m±SD) are calculated for those patients treated with rHuEpo at that time.
2rHuEpo doses (m±SD) of all patients of the group.
Delta rHuEpo(IU/week)
Delta ferritin( µg/l ) ferrogluconate/week in HD patients with and without Discussion rHuEpo; however, the decrease was significantly higher in those patients treated with rHuEpo. In HD patients, mild to moderate iron deficiency is the We found that following i.v. iron supplementation most common cause of rHuEpo hyporesponsiveness in rHuEpo could be significantly reduced in patients with haemodialysis patients. These patients have additional hypochromic RBC>6%. Therefore we conclude that iron loss as a result of blood loss into the haemodialyser, these rHuEpo-treated patients should receive concomitrepetitive phlebotomies for laboratory tests, and acciant i.v. iron treatment. A percentage of hypochromic dental bleeding from punctures. However, the diagnosis RBC>6% indicates a functional iron deficiency at a of iron deficiency is not easy in these patients, as
given dose of rHuEpo and reflects an imbalance between absolute and functional iron deficiency must be distingured cell proliferation and haemoglobin synthesis. ished. Although several factors have been investigated, In non-rHuEpo-treated patients with hypochromic so far no single indicator of the degree of iron deficiency RBC>6%, the percentage of the hypochromic RBC has been found. A serum ferritin value <100 mg/l decreases as well during i.v. iron supplementation. The indicates absolute iron deficiency. By this definition, six elevated hypochromic RBC in these patients might be of the 70 patients investigated had an absolute iron the eÂect of remnant endogenous erythropoietin producdeficiency at baseline. More recently measurement of tion. Similar to our findings in nine patients, Schaefer the percentage of hypochromic RBC has been recomand Schaefer [3] found that the percentage of the mended as an indicator of functional iron deficiency hypochromic RBC in uraemic patients without rHuEpo [1 ] , as newly formed RBC become hypochromic as a therapy can be normal even in the presence of iron consequence of the inadequate iron delivery by circulatdeficiency. Their explanation [3] was that the low ing transferrin to and the incomplete incorporation into erythropoietic activity in these patients combined with erythroid progenitor cells. a functional iron deficiency would not lead to the We therefore selected 70 HD patients to determine formation of hypochromic RBC. Therefore, we also whether the percentage of hypochromic RBC is a sensitrecommend administering i.v. iron to those HD patients ive indicator of functional iron deficiency. At the beginwhose hypochromic RBC are >6% and who are not ning of the study 17 patients had evidence of iron treated with rHuEpo. deficiency, defined by hypochromic RBC>10%, but Like Schaefer and Schaefer [3 ] we also found a there were 42 patients based on a cut-oÂ for functional significant negative linear correlation between serum iron deficiency of 5% hypochromic RBC. The percentferritin levels and percentage of hypochromic RBC after age of hypochromic RBC decreased during 4 weeks of i.v. iron supplementation with 80 mg of i.v. iron supplementation. The increases in serum ferritin levels in the 70 HD patients were extremely varied after inert. That is, it take weeks to get a signal up-or downintensive i.v. iron supplementation (800 mg ferroglucon-side (similar to HbA1c in diabetes mellitus). It is well ate within 12 weeks). In four patients there was no known that infection is a state of rHuEpo hyporesponsincrease in serum ferritin levels and another 14 patients iveness and sepsis a state of rHuEpo resistance. showed only moderately increased serum ferritin levels. Nonetheless, it has been shown that treatment of septic However, the rHuEpo doses in these 18 patients were patients with anti-TNF antibodies or interleukin recepsignificantly lower than in patients with higher increases tor antagonists resulted in a rHuEpo response in these in serum ferritin. Additionally, both their haemoglobin patients [10] . It is still controversial whether patients levels at 8 weeks and their haematocrit levels at 12 with infection should receive rHuEpo or not, and if so, weeks were significantly higher despite the lower then whether at the usual dosage or 2-3 times higher. rHuEpo doses. This could be explained by better iron Unclear is also whether iron therapy should be stopped utilization during erythropoiesis or by a higher respons-in such patients, as most investigators suggest. Our iveness to rHuEpo, as the hypochromic RBC were study demonstrates that even patients without clinical slightly higher in these patients. These data are consist-signs of inflammation or infection but with a positive ent with the well known fact that the synthesis of new CRP test do not react to i.v. iron supplementation with RBC requires large amounts of iron. a reduction of hypochromic RBC, in contrast to patients In patients receiving rHuEpo, inadequate iron supply with a negative CRP test. may occur even in the face of a normal or raised serum
In conclusion, our data indicate that the increase in ferritin level [8 ] . Therefore we subdivided our HD serum ferritin after i.v. iron supplementation and the patients according to their serum ferritin levels after 12 percentage of hypochromic RBC are adequate paraweeks of i.v. iron supplementation into those with serum meters with which to diagnose iron need and monitor ferritin <290 mg/l and those with serum ferritin iron therapy. However, this study also shows that some >290 mg/l at the end of the study ( Table 4) . rHuEpo patients do not respond in this manner to i.v. iron dose reduction could only be obtained in the former therapy. The observation that rHuEpo dosage could group of patients. These results suggest that in HD not be further reduced in the group of patients with patients increased serum ferritin after an i.v. iron dose serum ferritin levels between 290 and 1020 mg/l (median can be used as a parameter with which to assess iron 601 mg/l ) at the end of the study suggests that we need response: patients with a stable or moderate increase in to determine an upper limit of serum ferritin levels in serum ferritin respond better to rHuEpo than patients order to decide when to interrupt i.v. iron therapy. with a marked increase in serum ferritin (Table 4) .
Furthermore, marked increase in serum ferritin after These results lead one to suppose that the increase of i.v. iron is a 'postdictor' of reduced erythropoietic serum ferritin might be the consequence of an increased synthesis of ferritin by iron stored within the hepatocytes response. that is not mobilized and therefore not available for the incorporation into the erythroid progenitor cells.
